MA42597A - 2-amino-3-fluoro-3-(fluorométhyl)-6-méthyl-6-phényl-3,4,5,6-tétrahydropyridines comme inhibiteurs de bace1 - Google Patents

2-amino-3-fluoro-3-(fluorométhyl)-6-méthyl-6-phényl-3,4,5,6-tétrahydropyridines comme inhibiteurs de bace1

Info

Publication number
MA42597A
MA42597A MA042597A MA42597A MA42597A MA 42597 A MA42597 A MA 42597A MA 042597 A MA042597 A MA 042597A MA 42597 A MA42597 A MA 42597A MA 42597 A MA42597 A MA 42597A
Authority
MA
Morocco
Prior art keywords
tetrahydropyridines
fluoromethyl
fluoro
phenyl
amino
Prior art date
Application number
MA042597A
Other languages
English (en)
Inventor
Karsten Juhl
Mauro Marigo
Lena Tagmose
Original Assignee
H Lundbeck As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by H Lundbeck As filed Critical H Lundbeck As
Publication of MA42597A publication Critical patent/MA42597A/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002Heterocyclic compounds
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/72Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/72Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D211/74Oxygen atoms
    • C07D211/76Oxygen atoms attached in position 2 or 6
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
MA042597A 2015-08-12 2016-08-10 2-amino-3-fluoro-3-(fluorométhyl)-6-méthyl-6-phényl-3,4,5,6-tétrahydropyridines comme inhibiteurs de bace1 MA42597A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DKPA201500465 2015-08-12

Publications (1)

Publication Number Publication Date
MA42597A true MA42597A (fr) 2018-06-20

Family

ID=56615973

Family Applications (1)

Application Number Title Priority Date Filing Date
MA042597A MA42597A (fr) 2015-08-12 2016-08-10 2-amino-3-fluoro-3-(fluorométhyl)-6-méthyl-6-phényl-3,4,5,6-tétrahydropyridines comme inhibiteurs de bace1

Country Status (26)

Country Link
US (2) US10011596B2 (fr)
EP (1) EP3334720A1 (fr)
JP (1) JP2018531889A (fr)
KR (1) KR20180033524A (fr)
CN (1) CN107849011A (fr)
AR (1) AR105668A1 (fr)
AU (1) AU2016305275A1 (fr)
BR (1) BR112017007472A2 (fr)
CA (1) CA2993630A1 (fr)
CL (1) CL2018000375A1 (fr)
CO (1) CO2018000798A2 (fr)
CR (1) CR20180077A (fr)
DO (1) DOP2018000040A (fr)
EA (1) EA201890256A1 (fr)
EC (1) ECSP18010535A (fr)
HK (1) HK1253372A1 (fr)
IL (1) IL257007A (fr)
MA (1) MA42597A (fr)
MX (1) MX2018001699A (fr)
NI (1) NI201800020A (fr)
PE (1) PE20181015A1 (fr)
PH (1) PH12018500268A1 (fr)
RU (1) RU2018104868A (fr)
TN (1) TN2018000035A1 (fr)
TW (1) TW201718543A (fr)
WO (1) WO2017025559A1 (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CR20170187A (es) 2014-11-10 2018-02-01 H Lundbeck As 2-Amino-3,5-difluoro-6-metil-6-fenil-3,4,5,6-tetrahidropiridinas en calidad de inhibidores de BACE1 para el tratamiento de la enfermedad de Alzheimer
MA40941A (fr) 2014-11-10 2017-09-19 H Lundbeck As 2-amino-5,5-difluoro-6-(fluorométhyl)-6-phényl-3,4,5,6-tétrahydropyridines comme inhibiteurs de bace1
JO3458B1 (ar) 2014-11-10 2020-07-05 H Lundbeck As 2- أمينو-6- (دايفلوروميثيل) – 5، 5- ديفلورو-6-فينيل-3،4، 5، 6-تيتراهيدروبيريدين كمثبطات bace1
JO3627B1 (ar) 2015-04-30 2020-08-27 H Lundbeck As إيميدازو بيرازينونات على هيئة مثبطات pde1
TW201717948A (zh) 2015-08-10 2017-06-01 H 朗德貝克公司 包括給予2-胺基-3,5,5-三氟-3,4,5,6-四氫吡啶的聯合治療
US10034861B2 (en) 2016-07-04 2018-07-31 H. Lundbeck A/S 1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors
EP3532053A1 (fr) 2016-10-28 2019-09-04 H. Lundbeck A/S Traitements combinés comprenant l'administration d'imidazopyrazinones
LT3532064T (lt) 2016-10-28 2020-09-25 H. Lundbeck A/S Kompleksiniai gydymai, apimantys imidazopirazonus, skirti psichiatrinių ir (arba) kognityvinių sutrikimų gydymui
TW201829394A (zh) * 2016-12-21 2018-08-16 丹麥商H 朗德貝克公司 作為bace1抑制劑之6-胺基-5-氟-5-(氟甲基)-2,3,4,5-四氫吡啶-2-基-苯基-5-(甲氧基-d)-吡-2-甲醯胺及其氟化衍生物
RU2020118913A (ru) 2017-12-14 2022-01-14 Х. Лундбекк А/С (H. Lundbeck A/S) Виды комбинированного лечения, предусматривающего введение 1h-пиразолo[4,3-b]пиридинов
AR113926A1 (es) 2017-12-14 2020-07-01 H Lundbeck As Derivados de 1h-pirazolo[4,3-b]piridinas
JP7194738B2 (ja) 2017-12-20 2022-12-22 ハー・ルンドベック・アクチエゼルスカベット PDE1阻害剤としてのピラゾロ[3,4-b]ピリジン及びイミダゾ[1,5-b]ピリダジン
KR20210112968A (ko) 2020-03-07 2021-09-15 장성환 양면 인쇄가 가능한 라벨 제조방법
KR20230012296A (ko) 2021-07-15 2023-01-26 장성환 양면 인쇄가 가능한 라벨 제조방법

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002100399A1 (fr) 2001-06-12 2002-12-19 Elan Pharmaceuticals, Inc. Macrocycles utiles dans le traitement de la maladie d'alzheimer
GB0124928D0 (en) 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
DK1474395T3 (da) 2002-02-12 2008-02-11 Smithkline Beecham Corp Nicotinamidderivater, der er nyttige som p38-inhibitorer
AR077277A1 (es) 2009-07-09 2011-08-17 Lilly Co Eli Compuestos de biciclo (1,3)tiazin-2-amina formulacion farmaceutica que lo comprende y su uso para la manufactura de un medicamento util para el tratamiento de la enfermedad de alzheimer
CA2799640C (fr) 2010-06-09 2018-10-16 Janssen Pharmaceutica Nv Derives de 5,6-dihydro-2h-[1,4]oxazin-3-ylamine utiles comme inhibiteurs de beta-secretase (bace)
MX2013008111A (es) 2011-01-12 2013-10-30 Novartis Ag Derivados de oxazina y su uso en el tratamiento de transtornos neurologicos.
PT2663561E (pt) 2011-01-13 2016-06-07 Novartis Ag Derivados heterocíclicos novos e sua utilização no tratamento de distúrbios neurológicos
US8754075B2 (en) 2011-04-11 2014-06-17 Hoffmann-La Roche Inc. 1,3-oxazines as BACE1 and/or BACE2 inhibitors
EP2703399A4 (fr) 2011-04-26 2014-10-15 Shionogi & Co Dérivé d'oxazine et inhibiteur de bace 1 le contenant
US8987255B2 (en) 2011-06-07 2015-03-24 Hoffmann-La Roche Inc. Halogen-alkyl-1,3 oxazines as BACE1 and/or BACE2 inhibitors
UY34278A (es) 2011-08-25 2013-04-05 Novartis Ag Derivados novedosos de oxazina y su uso en el tratamiento de enfermedades
US8338413B1 (en) 2012-03-07 2012-12-25 Novartis Ag Oxazine derivatives and their use in the treatment of neurological disorders
US9493485B2 (en) 2012-03-20 2016-11-15 Imago Pharmaceuticals, Inc. Spirocyclic dihydro-thiazine and dihydro-oxazine BACE inhibitors, and compositions and uses thereof
WO2014056816A1 (fr) 2012-10-10 2014-04-17 F. Hoffmann-La Roche Ag Association d'un anticorps aβ et d'un inhibiteur de bace
WO2014065434A1 (fr) 2012-10-24 2014-05-01 Shionogi & Co., Ltd. Dérivés de dihydrooxazine ou d'oxazépine ayant une activité inhibitrice de bace1
EP2961749B1 (fr) 2013-03-01 2019-10-09 Amgen Inc. Composés perfluorés 5,6-dihydro-4h-1,3-oxazine-2-amine substitués en tant qu'inhibiteurs de la bêta-sécrétase et procédés d'utilisation correspondants
JO3318B1 (ar) 2013-06-18 2019-03-13 Lilly Co Eli مثبطات bace
TW201609700A (zh) * 2014-02-19 2016-03-16 H 朗德貝克公司 2-胺基-3,5,5-三氟-3,4,5,6-四氫吡啶作爲bace1抑制劑用於治療阿茲海默症
TW201623295A (zh) 2014-04-11 2016-07-01 塩野義製藥股份有限公司 具有bace1抑制活性之二氫噻及二氫衍生物
JO3458B1 (ar) * 2014-11-10 2020-07-05 H Lundbeck As 2- أمينو-6- (دايفلوروميثيل) – 5، 5- ديفلورو-6-فينيل-3،4، 5، 6-تيتراهيدروبيريدين كمثبطات bace1
CR20170187A (es) * 2014-11-10 2018-02-01 H Lundbeck As 2-Amino-3,5-difluoro-6-metil-6-fenil-3,4,5,6-tetrahidropiridinas en calidad de inhibidores de BACE1 para el tratamiento de la enfermedad de Alzheimer
MA40941A (fr) * 2014-11-10 2017-09-19 H Lundbeck As 2-amino-5,5-difluoro-6-(fluorométhyl)-6-phényl-3,4,5,6-tétrahydropyridines comme inhibiteurs de bace1
TW201717948A (zh) 2015-08-10 2017-06-01 H 朗德貝克公司 包括給予2-胺基-3,5,5-三氟-3,4,5,6-四氫吡啶的聯合治療

Also Published As

Publication number Publication date
RU2018104868A (ru) 2019-09-13
CR20180077A (es) 2018-04-09
PH12018500268A1 (en) 2018-08-13
AR105668A1 (es) 2017-10-25
CL2018000375A1 (es) 2018-07-06
DOP2018000040A (es) 2018-04-30
US10011596B2 (en) 2018-07-03
NI201800020A (es) 2018-06-29
AU2016305275A1 (en) 2018-02-08
CO2018000798A2 (es) 2018-05-10
HK1253372A1 (zh) 2019-06-14
ECSP18010535A (es) 2018-04-30
WO2017025559A1 (fr) 2017-02-16
KR20180033524A (ko) 2018-04-03
EP3334720A1 (fr) 2018-06-20
US20180244645A1 (en) 2018-08-30
MX2018001699A (es) 2018-05-07
TN2018000035A1 (en) 2019-07-08
US20170044151A1 (en) 2017-02-16
JP2018531889A (ja) 2018-11-01
BR112017007472A2 (pt) 2018-01-23
IL257007A (en) 2018-03-29
EA201890256A1 (ru) 2018-06-29
TW201718543A (zh) 2017-06-01
CA2993630A1 (fr) 2017-02-16
CN107849011A (zh) 2018-03-27
PE20181015A1 (es) 2018-06-26

Similar Documents

Publication Publication Date Title
MA42597A (fr) 2-amino-3-fluoro-3-(fluorométhyl)-6-méthyl-6-phényl-3,4,5,6-tétrahydropyridines comme inhibiteurs de bace1
IL290720A (en) Molecules for use in pest control, and intermediates, preparations, and processes related thereto
MA45591A (fr) Dérivés de 1,3-dihydroxy-phényle utiles comme immunomodulateurs
MA43761A (fr) 6-hydroxy-4-oxo-1,4-dihydropyrimidine-5-carboxamides comme inhibiteurs de la apj
MA41251A (fr) Dérivés de thiéno[2,3-c]pyrrol-4-one comme inhibiteurs erk
HRP20181698T1 (hr) 2-amino-6-(difluormetil)-5,5-difluor-6-fenil-3,4,5,6-tetrahidropiridini kao inhibitori bace1
MA40941A (fr) 2-amino-5,5-difluoro-6-(fluorométhyl)-6-phényl-3,4,5,6-tétrahydropyridines comme inhibiteurs de bace1
MA41977A (fr) Imidazopyrazinones utilisées comme inhibiteurs de pde1
ZA201701131B (en) Novel 2,5-substituted pyrimidines as pde4 inhibitors
IL252195A0 (en) Molecules with use in pest control, and intermediate products, preparations and processes related to them
EP3273075A4 (fr) Organe de fixation
EP3223820A4 (fr) Composés iminopyrimidinones condensés oxacycliques en c5-c6 utilisés comme inhibiteurs de bace, compositions et utilisation associées
EP3388693A4 (fr) Clip
HK1247927A1 (zh) 新型組合物、用途及其製備方法
FR3025204B1 (fr) Copolymeres a blocs utilisables comme fluidifiants
GB201513614D0 (en) Compositions, compounds and methods and uses relating thereto
EP3191447A4 (fr) Composés de s-imino-s-oxo iminothiazine en tant qu'inhibiteurs de bace, compositions, et leur utilisation
EP3274089A4 (fr) Composition de catalyseur présulfuré
EP3118227A4 (fr) Composition de 1-octène
MA42604A (fr) 2-amino-7a-phényl-3,4,4a,5,7,7a-hexahydrofuro[3,4-b]pyridines comme inhibiteurs de bace1
PT3335729T (pt) Composição de etanercept com estabilidade melhorada
ES1146958Y (es) Lama de persiana.
AU2015901323A0 (en) Slag notch
AU2015900494A0 (en) Rail clip tool